NVAAF
Nova Minerals Ltd
$0.6600
0.00%
No data for this timeframe.
Vol
SEC Reports13
Recent Activity
Jun 5, 2026
SEC
Nova Minerals is executing its redomiciliation from Australia to the United States, with trading halted across ASX, OTC,
6-K — Impact 4/10
Jun 3, 2026
SEC
Nova Minerals filed a 6-K attaching a press release requesting a voluntary suspension of trading of its shares on the AS
6-K — Impact 6/10
Jun 3, 2026
SEC
Nova Minerals Ltd filed a 6-K announcing that its schemes of arrangement, under which Nova Minerals Corp (US Holdco) wil
6-K — Impact 5/10
Analyst Ratings
1Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
13 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 10 neutral. Avg impact: 4.3/10.
NEUTRAL
6-K
4/10
Nova Minerals is executing its redomiciliation from Australia to the United States, with trading hal
Jun 5, 2026
BEARISH
6-K
6/10
Nova Minerals filed a 6-K attaching a press release requesting a voluntary suspension of trading of
Jun 3, 2026
NEUTRAL
6-K
5/10
Nova Minerals Ltd filed a 6-K announcing that its schemes of arrangement, under which Nova Minerals
Jun 3, 2026
NEUTRAL
6-K
5/10
Nova Minerals received Australian court approval for its schemes of arrangement to redomicile to the
Jun 2, 2026
NEUTRAL
6-K
5/10
Nova Minerals shareholders and listed warrantholders overwhelmingly approved the schemes of arrangem
Jun 1, 2026
BULLISH
6-K
6/10
Nova Minerals has commenced its fully funded 2026 exploration and development programs at the Estell
May 28, 2026
NEUTRAL
6-K
3/10
Nova Minerals filed a 6-K reminding shareholders and warrantholders of the upcoming Scheme Meetings
May 22, 2026
NEUTRAL
6-K
3/10
Nova Minerals CEO will present at the 2026 Alaska Sustainable Energy Conference, a high-profile gath
May 20, 2026
NEUTRAL
6-K
2/10
Nova Minerals filed a 6-K announcing a quarterly update webinar on May 21, 2026, where management wi
May 15, 2026
NEUTRAL
6-K
5/10
Nova Minerals announced that the Supreme Court of New South Wales has approved the convening of Sche
Apr 21, 2026
BULLISH
6-K
7/10
Nova Minerals announced a significant new gold anomaly at Portage Pass, located 2.5km from its estab
Apr 14, 2026
NEUTRAL
6-K
3/10
Nova Minerals Ltd announced the appointment of Ashlie Thorburn as Chief Financial Officer, effective
Apr 13, 2026
NEUTRAL
6-K
2/10
Nova Minerals Ltd filed a Form 6-K to submit its April 2026 corporate presentation, which was origin
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 80% buy across 5 analysts — 1 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| May 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Apr 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Mar 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Feb 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Jan 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.